These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 1827621

  • 1. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity.
    Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ.
    Clin Pharmacol Ther; 1991 May; 49(5):536-49. PubMed ID: 1827621
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.
    Kong AN, Ludwig EA, Slaughter RL, DiStefano PM, DeMasi J, Middleton E, Jusko WJ.
    Clin Pharmacol Ther; 1989 Dec; 46(6):616-28. PubMed ID: 2689044
    [Abstract] [Full Text] [Related]

  • 3. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics.
    Slayter KL, Ludwig EA, Lew KH, Middleton E, Ferry JJ, Jusko WJ.
    Clin Pharmacol Ther; 1996 Mar; 59(3):312-21. PubMed ID: 8653994
    [Abstract] [Full Text] [Related]

  • 4. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.
    Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E, Ferry JJ, Jusko WJ.
    Clin Pharmacol Ther; 1993 Oct; 54(4):402-14. PubMed ID: 8222483
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.
    Fisher LE, Ludwig EA, Wald JA, Sloan RR, Middleton E, Jusko WJ.
    Clin Pharmacol Ther; 1992 Jun; 51(6):677-88. PubMed ID: 1535301
    [Abstract] [Full Text] [Related]

  • 6. Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure.
    Jusko WJ, Milad MA, Ludwig EA, Lew KH, Kohli RK.
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S16-9. PubMed ID: 7781199
    [Abstract] [Full Text] [Related]

  • 7. The Pharmacokinetics and Pharmacodynamics of Methylprednisolone in Chronic Renal Failure.
    Milad MA, Ludwig EA, Lew KH, Kohli RK, Jusko WJ.
    Am J Ther; 1994 Jun; 1(1):49-57. PubMed ID: 11835067
    [Abstract] [Full Text] [Related]

  • 8. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.
    Yamashita SK, Ludwig EA, Middleton E, Jusko WJ.
    Clin Pharmacol Ther; 1991 May; 49(5):558-70. PubMed ID: 1827622
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease.
    Ludwig EA, Kong AN, Camara DS, Jusko WJ.
    J Clin Pharmacol; 1993 Sep; 33(9):805-10. PubMed ID: 8227476
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.
    Möllmann H, Rohdewald P, Barth J, Möllmann C, Verho M, Derendorf H.
    Pharm Res; 1988 Aug; 5(8):509-13. PubMed ID: 3072558
    [Abstract] [Full Text] [Related]

  • 11. Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism.
    Hon YY, Jusko WJ, Spratlin VE, Jann MW.
    J Clin Pharmacol; 2006 Apr; 46(4):408-17. PubMed ID: 16554448
    [Abstract] [Full Text] [Related]

  • 12. Modeling interactions between adrenal suppression and T-helper lymphocyte trafficking during multiple dosing of methylprednisolone.
    Chow FS, Sharma A, Jusko WJ.
    J Pharmacokinet Biopharm; 1999 Dec; 27(6):559-75. PubMed ID: 11153446
    [Abstract] [Full Text] [Related]

  • 13. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.
    Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ.
    Clin Pharmacol Ther; 1987 Oct; 42(4):465-70. PubMed ID: 3311551
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone.
    Daley-Yates PT, Gregory AJ, Brooks CD.
    Br J Clin Pharmacol; 1997 Jun; 43(6):593-601. PubMed ID: 9205819
    [Abstract] [Full Text] [Related]

  • 15. Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers.
    Ferry JJ, Della-Coletta AA, Weber DJ, VanderLugt JT.
    J Clin Pharmacol; 1994 Nov; 34(11):1109-15. PubMed ID: 7876403
    [Abstract] [Full Text] [Related]

  • 16. Methylprednisolone pharmacokinetics after intravenous and oral administration.
    Al-Habet SM, Rogers HJ.
    Br J Clin Pharmacol; 1989 Mar; 27(3):285-90. PubMed ID: 2655680
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous analysis of methylprednisolone hemisuccinate, cortisol and methylprednisolone by normal-phase high-performance liquid chromatography in human plasma.
    Kong AN, Slaughter RL, Jusko WJ.
    J Chromatogr; 1988 Nov 18; 432():308-14. PubMed ID: 3065346
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass.
    Kong AN, Jungbluth GL, Pasko MT, Beam TR, Jusko WJ.
    Pharmacotherapy; 1990 Nov 18; 10(1):29-34. PubMed ID: 2179900
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking.
    Milad MA, Ludwig EA, Anné S, Middleton E, Jusko WJ.
    J Pharmacokinet Biopharm; 1994 Dec 18; 22(6):469-80. PubMed ID: 7473077
    [Abstract] [Full Text] [Related]

  • 20. Steroid dose sparing: pharmacodynamic responses to single versus divided doses of methylprednisolone in man.
    Reiss WG, Slaughter RL, Ludwig EA, Middleton E, Jusko WJ.
    J Allergy Clin Immunol; 1990 Jun 18; 85(6):1058-66. PubMed ID: 2191992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.